Gyroscope Therapeutics Holdings plc announced that it will receive up to £44.5 million in an equity round of funding from new investor, Sanofi Ventures on November 8, 2021. The investor will invest £29.666666 million initially, at a premium to company's prior Series C financing, and the remaining £14.833333 million will be invested contingent on a future qualifying investment round and subject to the satisfaction of certain closing conditions. As a part of the transaction, a Sanofi R&D executive will join the company's Clinical Advisory Board.
Gyroscope Therapeutics Holdings plc
Equities
VISN
US40382N1037
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.75B | |
+8.57% | 41.34B | |
+49.22% | 41.61B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |